Search

Displaying results 1811 - 1820 of 10000 in total
  1. Drug

    Almasilate

    go.drugbank.com/drugs/DB13595
    Approved

    Almasilate is a buffering antacid that has been used in peptic ulcers and dyspepsia. … However its therapeutic efficacy is not comparable to other approved antacids, as it is no more effective in neutralizing acid and binding bile salts than other conventional antacids [A27138].

  2. Drug

    Rurioctocog alfa pegol

    go.drugbank.com/drugs/DB16007
    ApprovedInvestigational

    It was first approved by the European Commission in January 2018. … Factor VIII is an essential protein involved in normal blood clotting; thus, a deficient level of functional factor VIII is associated with an elevated risk for excessive bleeding caused by spontaneous

  3. Drug

    Triclabendazole

    go.drugbank.com/drugs/DB12245
    ApprovedInvestigational

    Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. … Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.

  4. Drug

    Ferric maltol

    go.drugbank.com/drugs/DB15598
    ApprovedInvestigational

    [A189291] Ferric maltol was initially granted FDA approval on July 25, 2019, for use in adults. … Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate

  5. Drug

    Tetraferric tricitrate decahydrate

    go.drugbank.com/drugs/DB14520
    ApprovedInvestigational

    Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. … [A25965] Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014.[L9926]

  6. Drug

    Pemigatinib

    go.drugbank.com/drugs/DB15102
    ApprovedInvestigational

    [A193719] FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast … [A193716] In April 2020, pemigatinib was approved by the FDA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously treated adult patients with a fibroblast

  7. Drug

    Plozasiran

    go.drugbank.com/drugs/DB18997
    ApprovedInvestigational

    [L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603] … Plozasiran contains a covalently linked ligand containing three N-acetylgalactosamine (GalNAc) residues to facilitate delivery to hepatocytes where it works to reduce triglyceride levels.

  8. Drug

    Emtricitabine

    go.drugbank.com/drugs/DB00879
    ApprovedInvestigational

    in high risk adolescents and adults. … Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults[L9019] or combined with [tenofovir alafenamide] for the prevention of HIV-1 infection

    Categories: Antivirals used in combination for the treatment of HIV infections
  9. Drug

    Cemiplimab

    go.drugbank.com/drugs/DB14707
    ApprovedInvestigational

    [A39201,A254177,L4615] It was later approved to be used in basal cell carcinoma and non-small non-small cell lung cancer. … [L43867] The EMA then approved Libtayo (cemiplimab) for that indication later in the same year. [L43872]

  10. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    safer for use in patients with contraindications to standard therapy. … [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and